With over 35 years of experience in the fields of law, finance and business management, healthcare and the pharmaceutical industry, Osagie is a co-founder of PIPV Capital, a Private Equity Firm that is focused on the Life Sciences vertical and has invested over $1 Billion in institutional money. Prior to co-founding PIPV Capital, he established GlaxoSmithKline Ventures and was its founding Vice President. Osagie has held senior commercial and R&D positions within pharmaceutical companies such as GSK, SmithKline, DuPont Merck and Endo. He has also been a Price Waterhouse Corporate Finance Partner as well as a practicing attorney with a leading US Law Firm, Schnader, Harrison, Segal & Lewis. Osagie is a serial entrepreneur and investor and serves as Chairman and Founder of Ibere Pharmaceuticals (NYSE:IBER) and Zelira Therapeutics (ASX:ZLD). He also serves on the Board of a number of financial institutions such as FS-KKR Capital Corp. (NYSE: FSK), Haverford Trust and Beltraith/StoneRidge Investment, institutions that cumulatively manage over $28 Billion. Osagie is a Trustee of the University of Pennsylvania, a member of the Executive Committee of the University, and is also the Chairman of the Board of the University of Pennsylvania Carey Law School.

Osagie holds post-graduate degrees from the University of Pennsylvania Carey Law School and the London School of Economics and is a member of the New York State Bar, in addition to other Bars.

Leave a Reply

Your email address will not be published.